DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.

ABSTRACT:

Purpose

DNA methyltransferase 3A (DNMT3A) is one of the commonly mutated genes in acute myelogenous leukemia (AML). Reports on the prognostic significance of DNMT3A mutations have been inconsistent, and most of the data are available only for patients 60 years of age or younger. We hypothesized that this inconsistency is due to an interaction between the dose of anthracycline used in induction therapy and DNMT3A status. We studied whether patients with DNMT3A-mutated AML treated with standard dose anthracyclines had an inferior survival compared with patients with other mutation profiles or those who received high-dose therapy.

Experimental design

A total of 152 patients in this retrospective cohort study (median age, 54 years) with de novo AML underwent induction therapy an

SUBMITTER: Sehgal AR 

PROVIDER: S-EPMC4383675 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature